Search Menu

Antiretrovirals

Roche withdraw application for Biojector needle-free option for T-20

Darunavir/r shows superiority over lopinavir/r at 48 weeks in TITAN trial

Maraviroc fails to show non-inferiority to efavirenz in treatment-naive patients: 48 week results

Importance of using maraviroc in combination with other active drugs in treatment-experienced patients

Week 48 raltegravir results in treatment-naive phase II dose-finding study

DUET studies clarify antiviral efficacy of etravirine and cross-resistance profile to other NNRTIs

Boosting atazanavir in treatment-naive patients, and impact on lipids after switching from lopinavir/r

Saquinavir/r vs lopinavir/r in treatment-naive patients

Fosamprenavir/r vs atazanvir/r in treatment-naive patients

Maraviroc approved in the US

Monogram launches Trofile HIV co-receptor tropism test

Raltegravir (MK-0518) phase 3 trials show successful viral suppression in multi-drug resistant patients

Maraviroc phase 2b/3 results in treatment experienced CCR5-tropic patients

Phase 2 study of GileadÂ’s integrase inhibitor elvitegravir (GS-9137)

Phase 2b study comparing rilpivirine (TMC-278) to efavirenz in treatment-naive patients: 48-week results

PK results from heat-stable formulation of ritonavir

Use of low-dose rapamycin, a CCR5 suppressant, to increase potency of T-20 in vitro

Darunavir (TMC-114) approved in Europe

No significant interaction reported between etravirine (TMC125) and raltegravir (MK-0518)

Future of second-generation fusion inhibitors less certain as Trimeris and Roche separate

Pharmacokinetic study of Triomune-40 in Malawi: higher d4T exposure suggests importance of using lower dose formulations of d4T

GSK stops development of brecanavir

FDA analysis of predicted responses to tipranavir/r

Important changes to US prescribing information for efavirenz

Changes to US product label for T-20 (enfuvirtide)

Explanation for failure of TMC-125 (etravirine) in TMC227 study

Saquinavir/r vs lopinavir/r: interim results from the Gemini study

TMC 114 recommended for conditional approval in Europe

Atazanavir 300mg capsule approved in US

Lipid profile of integrase inhibitor MK-0518: 24 week results compared to efavirenz in treatment naive patients

NRTI elvucitabine active against HIV in a 7-day monotherapy study

Efavirenz/tenofovir fails as 2-drug maintenance regimen

Early access programme for MK-0518 integrase inhibitor

Etravirine (TMC-125) available on named patient programme in the UK

Fixed dose combination (FDC) of tenofovir/FTC/efavirenz (Atripla) filed in EU

Tipranavir available in Scotland – almost one year after EU approval

FDA decision delayed on Biojector for administering T-20 pending additional safety information

Integrase inhibitor MK-0518: early results show greater early potency than efavirenz

Maraviroc results in R5/X4 mixed/dual tropic patients: unexpected safety data shows possible immunolocical effect

Vicriviroc 24-week results in triple-class experienced R5-tropic patients

Etravirine (TMC-125) associated with -1 log viral load reduction at 48-weeks results in treatment experienced patients

Three-class experienced patients experience 1 log viral load reduction using monoclonal antibody TNX-355

New data on darunavir (TMC-114)

Lopinavir/r monotherapy: less potent than triple therapy with higher risk of resistance

Atazanavir/r monotherapy and CNS penetration

Fosamprenavir/r is non-inferior to Kaletra in treatment naive patients

Tenofovir/FTC maintains greater virological response and reduced lipoatrophy compared to AZT/3TC after 96 weeks

Antiretroviral effect of foscarnet in patients with multiple drug resistance in late stage HIV disease

New formulation of lopinavir/r approved in Europe (Kaletra) and new tradename for access countries (Aluvia)

US approval for darunavir (TMC-114, Prezista)

Boehringer stops tipranavir trial in treatment-naive patients

FDA approves fixed-dose combination of efavirenz/tenofovir/FTC (Atripla): joint company collaboration produces once-daily one pill combination

Evidence that CCR5 is protective against West Nile virus: implications for CCR5 inhibitors

Efavirenz levels above recommended upper target in 20% of African patients in Senegal

Lower dose of AZT provides adequate exposure in patients with low body weight

Fixed-dose formulation of efavirenz/tenofovir/FTC bioequivalent to separate dosing

Saquinavir/r (1000/100mg) levels reduced when taken fasted and should be taken with food

Lack of food effect with Meltrex formulation of lopinavir/r

Food interaction reduces ddI intracellular absorption and supports requirement to take fasted

Conflicting results on how T-20 affects tipranavir

Development of d-d4FC (dexelvucitabine, Reverset) discontinued

Other new antiretrovirals at Denver: the future seems bright

Early integrase inhibitor studies in treatment experienced patients raise hopes for new drugs in a new class

Atazanavir in treatment naive patients, with and without ritonavir boosting

CNS penetration of ARV drugs is associated with lower CSF viral load

Post navigation